cancer treatment

Cancer treatment is a major area where nanotechnology is expected to play a big role in. The science and engineering of controlling matter, at the molecular scale, to create devices with novel chemical, physical and/or biological properties—has the potential to radically change how cancer is diagnosed and treated.

  • "Krebserzeugende Gefahrstoffe in der Arbeitswelt" Jahrestagung LIA

    Belastungen durch krebserzeugende Gefahrstoffe bei der Arbeit stellen nicht nur kleine und mittlere Betriebe vielfach noch vor Probleme. Nach wissenschaftlichen Schätzungen sind vermutlich fünf Prozent der jährlich knapp 500.000 Krebsneuerkrankungen in Deutschland berufsbedingt.

  • Cancer Research - How Cells Die by Ferroptosis

    A Fibroblast Undergoing Ferroptosis. Source: Helmholtz Zentrum München

    Ferroptosis is a recently discovered form of cell death, which is still only partially understood. Scientists at the Helmholtz Zentrum München have now identified an enzyme that plays a key role in generating the signal that initiates cell death. Their findings, published in two articles in the journal ‘Nature Chemical Biology’, could now give new impetus to research into the fields of cancer, neurodegeneration and other degenerative diseases. The term ferroptosis was first coined in 2012. It is derived from the Greek word ptosis, meaning “a fall”, and ferrum, the Latin word for iron, and describes a form of regulated necrotic cell death in which iron appears to play an important role.

  • CRISPR/Cas9 technology to inactivate cancer mutations

    As for many other biomedical and biotechnology disciplines, the genome scissor “CRISPR/Cas9” also opens up completely new possibilities for cancer research. Scientists of the National Center for Tumor Disease (NCT), the German Consortium for Translational Cancer Research (DKTK) and the Medical Faculty of the TU Dresden have shown that mutations that act as cancer drivers can be targeted and repaired. The most relevant mutations could therefore be diagnosed faster, improving personalized therapies.

  • Einsatz neuer Krebsmedikamente: Die Biologie entscheidet

    Jahrestagung 2016

    Leipzig/Berlin, 5. September 2016 – Lange galt der Ursprungsort einer Krebserkrankung als entscheidend für die medikamentöse Behandlung. Diese Regel gilt nicht mehr. Sowohl bei den Arzneimitteln als auch bei der Immuntherapie richtet sich der Einsatz nach biologischen Kriterien. Die Jahrestagung der deutschsprachigen Fachgesellschaften für Hämatologie und Medizinische Onkologie bietet den Teilnehmerinnen und Teilnehmern einen Überblick über die neuesten wissenschaftlichen Erkenntnisse im Bereich der Immuntherapie und die Möglichkeit, im kollegialen Dialog Erfahrungen auszutauschen.

  • Every atom counts in Protein structures

    Every atom counts in Protein structures | Tailored parallel X-rays perfectly matching the dimensions of the protein crystals enabled the scientists to determine the proteasome structure in unprecedented detail. Illustration: Hartmut Sebesse / Max Planck Institute for Biophysical Chemistry

    Malignant cancer cells not only proliferate faster than most body cells. They are also more dependent on the most important cellular garbage disposal unit, the proteasome, which degrades defective proteins. Therapies for some types of cancer exploit this dependence: Patients are treated with inhibitors, which block the proteasome. The ensuing pile-up of junk overwhelms the cancer cell, ultimately killing it. Scientists have now succeeded in determining the human proteasome’s 3D structure in unprecedented detail and have deciphered the mechanism by which inhibitors block the proteasome. Their results will pave the way to develop more effective proteasome inhibitors for cancer therapy.

  • Nanotechnology Supports Treatment of Malignant Melanoma

    The cantilever bears the recognition sequence for the target mutation. If this is present in the sample, the corresponding segment of RNA binds to the cantilever, causing the latter to bend. University of Basel, Department of Physics

    Changes in the genetic make-up of tissue samples can be detected quickly and easily using a new method based on nanotechnology. This report researchers from the Swiss Nanoscience Institute, the University of Basel and the University Hospital Basel in first clinical tests with genetic mutations in patients with malignant melanoma. The journal Nano Letters has published the study.

  • Researchers Discover New Regulator in Glucose Metabolism

    Immunofluorescence microscopy of TSC22D4 (red) expressing cells. Source: Helmholtz Zentrum München

    A key genetic switch in the liver regulates glucose metabolism and insulin action in other organs of the body. Researchers of Helmholtz Zentrum München, in collaboration with colleagues of the Heidelberg University Hospital, Technische Universität München and the Medical Faculty of the University of Leipzig, have now reported these findings in the journal ‘Nature Communications’. Diabetes mellitus is a chronic disease that has become increasingly prevalent in the population: More than six million people are affected by the disease alone in Germany. It is characterized by a disruption of the glucose metabolism and (except for type 1 diabetes) an impaired response of the body to the hormone insulin. Scientists are currently seeking to find the cause and possible regulators of the disease in order to intervene therapeutically.

  • Selective manipulation of enzyme can stop cancer cachexia

    Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme can stop unwanted metabolic processes.

  • Selenversorgung beeinflusst Risiko für Krebsentwicklung

    Charité-Wissenschaftler untersuchen Zusammenhänge

    Das Spurenelement Selen ist ein essentieller Nahrungsbestandteil. Wie Wissenschaftler der Charité – Universitätsmedizin Berlin in Zusammenarbeit mit der International Agency for Research on Cancer nun zeigen konnten, sorgt ein hoher Selenwert im Blut für ein vermindertes Risiko, an Leberkrebs zu erkranken. Die aktuelle Studie hat auch weitere Risikofaktoren einbezogen und den Einfluss der Selenversorgung auf die Entwicklung anderer Krebsarten betrachtet. Die Ergebnisse sind im Fachmagazin American Journal of Clinical Nutrition* veröffentlicht.

  • Spezifisch bindender Radioligand ermöglicht neuen Operationsansatz für Prostatakrebs

    Spezifisch bindender Radioligand ermöglicht neuen Operationsansatz für Prostatakrebs | Durch an der TUM entwickelten Radioliganden können auch sehr kleine Metastasen sichtbar gemacht werden. Auf dieser PET/CT-Aufnahme ist ein veränderter Lymphknoten zu erkennen (Pfeil). Foto: Nuklearmedizin / TUM

    Prostatakrebs ist eine der häufigsten Krebserkrankungen bei Männern. Selbst nachdem die Prostata operativ entfernt wurde, können sich in Lymphknoten im Becken neue Metastasen bilden. Forscherinnen und Forscher der Fakultäten für Medizin und Chemie an der Technischen Universität München (TUM) haben gemeinsam eine Methode entwickelt, mit der diese Tochtergeschwüre sichtbar gemacht und entfernt werden können, wenn sie noch sehr klein sind. Dazu wird ein Radioligand in den Blutkreislauf injiziert, der sich selektiv an ein Protein bindet, welches im menschlichen Körper sonst sehr selten ist.

  • Successfully Treating Genetically Determined Autoimmune Enteritis

    Poor to moderately differentiated adenocarcinoma of the stomach. H&E stain.

    Using targeted immunotherapy, doctors have succeeded in curing a type of autoimmune enteritis caused by a recently discovered genetic mutation. This report comes from researchers at the Department of Biomedicine of the University of Basel and University Hospital Basel. Their results raise new possibilities for the management of diarrhea, which is often a side effect of melanoma treatment. Immunodeficiencies can arise due to gene mutations in immune system proteins. As such mutations rarely occur, these immunodeficiencies often go unrecognized or are detected too late for effective treatment. Currently, there are more than 300 different known genetically determined immunodeficiencies, with new examples being described almost every week.